Close Menu

More articles about Point-of-Care Testing

The study showed that the Zeesan test kit and qPCR instrument could be used for near-patient HPV typing of 94 samples in 2.5 hours.

The resulting company will retain the Lumos name and focus on the international launch of RPS' FebriDx test for febrile acute respiratory infections.

The self-administered test is designed to detect human chorionic gonadotropin levels in women as early as six days before a first missed period.

The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.

The firms anticipate discovering and validating a biomarker signature, or signatures, for earlier detection of pulmonary hypertension and its subtypes.

After conducting a head-to-head comparison with competing instruments, clinicians selected the Abbott iStat instrument to monitor blood clotting during surgical interventions.

The firm is developing a multipanel test and an antibiotic resistance panel to augment its recently CE marked chlamydia and gonorrhea assay.

The firm reported declines in revenues from its molecular collections systems, genomics products, and infectious disease tests, but still beat analyst estimates.

The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.

The firm said it has multiple point-of-care tests available in Brazil and anticipates soon fulfilling an order for its dengue, chikungunya, and Zika tests.

Cincinnati, Ohio-based Meridian will acquire Quebec City-based GenePOC for $120 million, and hopes to quickly convert customers to a PCR-based instrument.

The firm said that its nucleic acid amplification test provides viral load measurements of HIV type 1 groups M/N and O, and HIV-2 within 70 minutes

The company missed the consensus Wall Street estimates on both the top and bottom lines, while its R&D spending and SG&A costs grew significantly.

The firm said that its point-of-care test delivers laboratory-quality results in about 30 minutes and could be used in the home and other settings.

Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.

Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.

The firm said that the test, a hematology-based cellular biomarker that identifies morphological changes within monocyte white blood cells, could speed diagnosis.

The microfluidic immunoassay uses spectrometry and a lateral flow method to diagnose the "very large global health problem" in about 20 minutes.

Within the diagnostics business, Abbott's core laboratory sales grew 4 percent but its other diagnostic segments were down year over year.

The company envisions creating a "vocometer … to provide disease screening and management solutions based on acoustic analysis of seconds of voice."

Pages